Oral 5-aminolevulinic acid administration before transurethral resection of bladder tumor induces perioperative nausea and vomiting

• Published in: Photodiagnosis and photodynamic therapy 2023-09, Vol.43, p.103707-103707, Article 103707
• Main Authors: Taoka, Rikiya, Yamada, Keisuke, Sawanobori, Yoshiharu, Honda, Tomoko, Osaki, Yu, Abe, Yohei, Naito, Hirohito, Tohi, Yoichiro, Matsuoka, Yuki, Kato, Takuma, Okazoe, Homare, Ueda, Nobufumi, Sugimoto, Mikio
• Format: Article
• Language: English
• Subjects: 5-aminolevulinic acid; Nausea; Transurethral resection of bladder tumor; Vomiting
• ISSN: 1572-1000; 1873-1597
• DOI: 10.1016/j.pdpdt.2023.103707

•5-aminolevulinic acid (5-ALA) is an oral photodynamic diagnostic agent.•One in ten patients developed nausea and vomiting within four hours post 5-ALA use.•5-ALA induced postoperative nausea and vomiting in 25.7% of the patients.•5-ALA use was independently associated with postoperative nausea and vomiting.•5-ALA=5-aminolevulinic acid. The efficacy of photodynamic diagnosis using 5-aminolevulinic acid during transurethral resection of bladder tumors has been demonstrated, albeit with limited information regarding its side effects. This study aimed to clarify the impact of oral 5-aminolevulinic acid on perioperative nausea and vomiting (NV) for the first time in a real-world clinical practice setting. Patients who underwent transurethral surgery at Kagawa University between April 2017 and March 2020 were included. Perioperative NV and antiemetic use status were prospectively assessed and compared between the patients who received oral 5-aminolevulinic acid and those who did not. Additionally, univariate and multivariate analyses were performed for predicting postoperative nausea and vomiting. Of 214 patients, 74 (34.6%) received oral 5-aminolevulinic acid preoperatively. The proportions of preoperative NV and antiemetic use in the patients who received 5-aminolevulinic acid were 9.5% and 4.1%, respectively, and higher than in those who did not (0% and 0%; P